Benefits of direct high-throughput cell counting in immuno-oncology research

Antibody-directed and drug therapies have been on the forefront of immuno-oncology research in the past 15 years. Since the FDA introduced the Breakthrough Therapy Designation in 2016 for novel promising drug therapies, the number of applicants and approved candidates has increased dramatically. As more and more researchers are looking at drug effects in cancer cells and moving forward in drug discovery, they face many challenges in their day to do work. Performing cell cytotoxicity assays for multiple cell lines with single and combination drug therapies is standard practice in immuno-oncology. While many researches use end-point assays such as MTT, XTT, WST, or CellTiter-Glo, others prefer the manual [...]

Cellometer assists in identification of PGRMC as a cancer stem cell marker and therapeutic target

The University of Kentucky investigated progesterone receptor membrane component 1 (PGRMC1), an often upregulated component in thyroid, breast, colon and lung tumors. PGRMC1 has been associated with drug resistance and is thought of as an indicator of prognosis. The researchers employed a variety of cell types to represent head and neck cancers, as well as oral, lung and ovarian cancers. These cells were exposed to PGRMC1 inhibitors. The Cellometer performed cell counts with Trypan Blue. The PGRMC1 inhibitors successfully prompted cancer stem cell death even when other anti-cancer agents did not. The researchers suggest using PGRMC1 as a cancer stem [...]